Geode Capital Management
LBPH

Geode Capital Management’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Geode Capital Management’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-746,147
Closed -$24.9M – 4608
2024
Q3 		$24.9M Buy
746,147
+63,756
+9% +$2.2M ﹤0.01% 1861
2024
Q2 		$18.4M Buy
682,391
+126,308
+23% +$2.49M ﹤0.01% 1970
2024
Q1 		$12M Buy
556,083
+221,422
+66% +$4.83M ﹤0.01% 2213
2023
Q4 		$2.02M Buy
334,661
+2,972
+0.9% +$14.8K ﹤0.01% 3101
2023
Q3 		$1.84M Buy
331,689
+1,982
+0.6% +$12.8K ﹤0.01% 3097
2023
Q2 		$2.42M Buy
329,707
+247,801
+303% +$1.88M ﹤0.01% 3052
2023
Q1 		$322K Buy
81,906
+962
+1% +$4.7K ﹤0.01% 3831
2022
Q4 		$255K Buy
80,944
+736
+0.9% +$2.95K ﹤0.01% 3961
2022
Q3 		$298K Buy
80,208
+64,677
+416% +$239K ﹤0.01% 3991
2022
Q2 		$47K Buy
15,531
+354
+2% +$1.63K ﹤0.01% 4791
2022
Q1 		$78K Hold
15,177
– – ﹤0.01% 4719
2021
Q4 		$73K Hold
15,177
– – ﹤0.01% 4797
2021
Q3 		$135K Buy
+15,177
New +$140K ﹤0.01% 4586

Geode Capital Management's LBPH Position: Q4 2024 in Review

Geode Capital Management sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 746,147 shares — an estimated $24.9M sold.

Geode Capital Management first reported a position in LBPH in Q3 2021 and held it in 13 quarters. The position peaked at $24.9M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

  • Geode Capital Management reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Geode Capital Management sold 746,147 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $24.9M.
  • Geode Capital Management first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 13 quarters.
  • Geode Capital Management's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $24.9M in Q3 2024.
  • 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Geode Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.